DENVER, Oct. 30, 2017 /PRNewswire/ -- Abbott (NYSE:
ABT) today announced that patients who underwent
minimally-invasive implantation with a XIENCE coronary stent for
left-main coronary artery disease had the same long-lasting health
outcomes at three years but felt better more quickly than patients
who underwent open-heart surgery.
The data were presented during a late-breaking session at the
29th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the
annual scientific symposium of the Cardiovascular Research
Foundation.
"For any treatment, it's important to not only consider clinical
outcomes such as recurrent heart attacks or stroke, but also to
consider the effect of the treatment on a patient's quality of
life," said Suzanne J. Baron, M.D.,
study investigator and assistant professor of medicine at the
University of Missouri-Kansas City.
"These data demonstrate that PCI is a reasonable treatment option
for patients with left main coronary artery disease that allows
them to potentially avoid surgery and to rapidly obtain a better
quality of life after revascularization."
Quality-of-life was assessed at baseline, one month, one year,
and three years. Patients were asked to report frequency of chest
discomfort (angina), difficulty breathing, symptoms of depression
and other physical and mental limitations.
After one month, patients who underwent percutaneous coronary
intervention with XIENCE reported significantly greater freedom
from angina (72 percent vs 70 percent; p<0.01); no difficulty
breathing (60 percent vs 44 percent; p<0.01); and significantly
fewer symptoms of clinical depression (8 percent vs 19 percent;
p<0.01) than patients who had surgery. The significantly fewer
symptoms of clinical depression extended to one year for XIENCE
patients versus surgery patients (8 percent vs 12 percent; p=0.03)
and were comparable by year three (9 percent vs 8 percent;
p=0.77).
Freedom from angina and difficulty breathing were comparable
after one year and maintained out to three years. Eighty-one
percent of patients in the XIENCE group reported freedom from chest
discomfort at three years compared with 82 percent in the surgery
group (p=0.10). Forty-three percent of patients who received XIENCE
vs 42 percent of surgery patients reported no difficulty in
breathing at year three (p=0.77). The findings were consistent
across different types of patients including people with diabetes,
frequent chest pain before treatment and people over the age of
75.
"For years, we've debated over the best way to restore vessel
function to patients with coronary artery disease," said
Charles Simonton, M.D., chief
medical officer of Abbott's vascular business. "It's important to
weigh the benefits and risk of any treatment, and these data
provide confidence that XIENCE can be considered as a potential
option for many types of patients with coronary artery disease,
including those with left-main disease."
About coronary artery disease:
Coronary artery disease is caused when cholesterol and fat build up
inside the arteries that supply oxygen-rich blood to the heart. If
blood flow to the heart is reduced or blocked, a person can
experience chest discomfort (angina) or heart attack.1
Left-main coronary artery disease affects the artery that feeds
blood to the left side of the heart, and is associated with
increased chance of heart attack and poorer clinical outcomes
compared with other types of coronary artery disease.
About the study:
The quality-of-life analysis was
conducted based on data from the XIENCE EXCEL study (n=1,905), an
international, open-label, multicenter randomized trial that
compared the safety and efficacy of percutaneous coronary
intervention with XIENCE versus surgery known as coronary artery
bypass grafting (CABG) in patients with left main coronary artery
disease. Quality-of-life was assessed at baseline, one month, one
year and three years using the Seattle Angina Questionnaire (SAQ),
the 12-item Short Form Health Survey (SF-12), the Rose Dyspnea
Scale (RDS), the Patient Health Questionnaire (PHQ-8), and the
EuroQOL (EQ-5D).
About XIENCE:
The XIENCE family of everolimus-eluting
coronary stent systems are indicated for improving coronary luminal
diameter in patients, including people with diabetes mellitus, de
novo chronic total coronary occlusions, and people with symptomatic
heart disease due to de novo native coronary artery lesions. XIENCE
has an unprecedented safety profile, with consistent low rates of
stent thrombosis, even in complex cases.6,7 A special
coating on XIENCE interacts with proteins in the blood to reduce
the risk for blood clots in the stent. For more information visit
www.XienceProof.com/US.
For U.S. Important Safety Information, visit:
https://vascular.abbott.com/Xience-Stent-Safety.html#isi
About Abbott:
At Abbott, we're committed to helping
you live your best possible life through the power of health. For
more than 125 years, we've brought new products and technologies to
the world -- in nutrition, diagnostics, medical devices and branded
generic pharmaceuticals -- that create more possibilities for more
people at all stages of life. Today, 94,000 of us are working to
help people live not just longer, but better, in the more than 150
countries we serve.
Connect with us at www.abbott.com, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
__________________________________________
1 National Heart, Lung, and Blood Institute. What Is
Coronary Heart Disease?
https://www.nhlbi.nih.gov/health/health-topics/topics/cad. Accessed
October 17, 2017.
View original content with
multimedia:http://www.prnewswire.com/news-releases/analysis-of-landmark-study-showed-patients-treated-for-left-main-coronary-artery-disease-with-xience-stent-felt-better-faster-and-had-similar-long-term-outcomes-to-open-heart-surgery-300545236.html
SOURCE Abbott